What are the current clinical variants of squamous cell carcinoma and their recommended diagnostic and management approaches?

Clinical Variants of Squamous Cell Carcinoma: Diagnosis and Management

Squamous cell carcinoma presents in distinct anatomic and histologic variants that require tailored diagnostic and therapeutic approaches, with cutaneous SCC managed primarily through surgical excision and head/neck SCC through multimodal therapy incorporating HPV status stratification.

Anatomic Classification and Epidemiology

SCC divides into two major categories based on anatomic site, each with distinct clinical behavior:

Cutaneous Squamous Cell Carcinoma (cSCC)

• Accounts for 20%-25% of all skin tumors with variable metastatic potential based on histologic subtype 1
• Risk stratification is critical: low-risk variants have ≤2% metastatic rate, intermediate 3-10%, and high-risk >10% 2

Head and Neck Squamous Cell Carcinoma (SCCHN)

• Represents the seventh most common cancer worldwide with approximately 700,000 new cases annually 1
• Five-year survival varies dramatically by site: laryngeal (61%), oral cavity (49%), oropharyngeal (41%), and hypopharyngeal (25%) 1
• HPV-positive oropharyngeal cancer (30-35% of cases) demonstrates significantly better outcomes than HPV-negative disease 1

Histologic Variants and Risk Stratification

Low-Risk Cutaneous Variants (≤2% metastatic rate)

• SCC arising in actinic keratosis 2
• HPV-associated SCC 2
• Tricholemmal carcinoma 2
• Spindle cell SCC (when unassociated with radiation) 2

Intermediate-Risk Cutaneous Variants (3-10% metastatic rate)

• Adenoid (acantholytic) SCC 2
• Intraepidermal epithelioma with invasion 2
• Lymphoepithelioma-like carcinoma 2

High-Risk Cutaneous Variants (>10% metastatic rate)

• De novo SCC 2
• SCC arising from radiation, burn scars, or in immunosuppressed patients 2
• Invasive Bowen's disease 2
• Adenosquamous carcinoma 2

Head and Neck Variants

• Verrucous, papillary, spindle cell, basaloid, and acantholytic variants each present unique diagnostic challenges 3, 4
• Nuclear protein in testis (NUT) midline carcinoma represents a distinct molecular entity requiring specific identification 3
• Viral-related carcinomas (HPV and EBV-associated) must be distinguished from non-viral forms due to prognostic and therapeutic implications 3

Diagnostic Approach

Cutaneous SCC Biopsy Technique

Punch biopsy, shave biopsy, or excisional biopsy are recommended, with technique selection based on lesion morphology and location 1

Critical biopsy requirements:

• Adequate depth to reach mid-subcutaneous adipose tissue for accurate microstaging 1
• Modified Breslow measurement excluding parakeratosis/scale-crust, measured from ulcer base if present 1
• Repeat biopsy if initial specimen inadequate for accurate diagnosis 1
• Provide pathologist with clinical history including radiation exposure, burns, organ transplantation status 1

Head and Neck SCC Evaluation

Flexible head and neck fibreoptic endoscopy with biopsy under local anesthesia is mandatory for pathological confirmation 1

Essential workup components:

• Complete physical examination including neck palpation 1
• Performance status, nutritional status with weight assessment 1
• Dental examination, speech and swallowing function evaluation 1
• Laboratory assessment: complete blood count, liver enzymes, serum creatinine, albumin, coagulation parameters, TSH 1
• HPV testing for all oropharyngeal cancers given prognostic significance 1

Advanced Diagnostic Modalities

Emerging techniques include:

• High-frequency ultrasonography and optical coherence tomography for improved tumor characterization 5
• Frozen section analysis demonstrates 86% sensitivity and 100% specificity for HPV-associated SCC of unknown primary 6
• Reflectance confocal microscopy and dermoscopy enhance diagnostic accuracy 5

Management Strategies

Low-Risk Cutaneous SCC

Standard excision with 4-6 mm margins to mid-subcutaneous adipose tissue depth with histologic margin assessment is recommended 1

Alternative approaches:

• Curettage and electrodesiccation may be considered for low-risk primary cSCC in non-terminal hair-bearing locations 1
• Radiation therapy can be considered when surgery not feasible, though cure rates may be lower 1
• Cryosurgery only when more effective therapies contraindicated 1

Critical caveat: Topical therapies (imiquimod, 5-FU) and photodynamic therapy are NOT recommended for cSCC treatment based on available data 1

High-Risk Cutaneous SCC

Mohs micrographic surgery (MMS) is recommended for high-risk cSCC due to superior margin control 1

• Standard excision may be considered for select high-risk tumors, but strong caution advised without complete margin assessment 1
• Treatment planning must consider recurrence rate, functional preservation, and patient expectations 1

Head and Neck SCC

Management varies by stage and HPV status:

For localized disease:

• Surgical resection remains primary treatment for most sites 1
• Radiation therapy as definitive treatment for selected cases 1

For locally advanced disease:

• Multimodal therapy incorporating surgery, radiation, and systemic therapy 1
• HPV-positive oropharyngeal cancer patients may be candidates for de-escalation strategies given superior prognosis 1

Advanced/Metastatic Disease

Surgical resection with or without adjuvant radiation therapy and possible systemic therapy are recommended for regional lymph node metastases 1

Systemic therapy options:

• Epidermal growth factor inhibitors and cisplatin (single agent or combination) may be considered for metastatic disease 1
• Immunotherapy with cemiplimab and pembrolizumab has revolutionized treatment for advanced cSCC 7
• Combination chemoradiation therapy for inoperable disease 1

Multidisciplinary consultation is mandatory for patients with locoregional or distant metastases, particularly in immunosuppressed individuals 1

Follow-Up and Surveillance

After first SCC diagnosis, screening for new keratinocyte cancers and melanoma should be performed at least annually 1

• Patients with history of cSCC require counseling on skin self-examination 1
• Best supportive and palliative care should be provided to patients with advanced disease to optimize symptom management and quality of life 1

Critical Pitfalls to Avoid

1. Never use topical therapies or PDT as primary treatment for invasive cSCC—these modalities lack efficacy data 1

2. Do not perform standard excision on high-risk tumors without complete margin assessment—this significantly increases recurrence risk 1

3. Always test oropharyngeal cancers for HPV status—this fundamentally alters prognosis and may influence treatment intensity 1

4. Ensure adequate biopsy depth—superficial biopsies prevent accurate microstaging and risk stratification 1

5. Recognize that immunosuppressed patients require heightened surveillance and multidisciplinary management given increased metastatic risk 1, 2